SPRO
Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (SPRO) has 13 SEC Form 4 filings (18 transaction rows) in the rolling window, disclosed by 2 distinct insiders. Most recent filing: Aug 6, 2026.
The most active filer is Chief Operating Officer Keutzer Timothy with 4 filings. Insiders have net sold $315K over the trailing 6 months.
- Industry:Biotechnology
- CEO:Esther Rajavelu
- Employees:32
- HQ:Cambridge, MA, US
- IPO:2017-11-02
Insider Buying
$0
reported purchases (SEC code P)
Insider Selling
$457K
reported sales (SEC code S)
Unique Insiders
2
in the rolling window
Market Cap
$73.5M
latest known value
| Source | ||||||
|---|---|---|---|---|---|---|
| See Remarks | Sale | 25,240 | $63K | May 7 | SEC ↗ | |
| See Remarks | Sale | 87,917 | $207K | Feb 9 | SEC ↗ | |
| Chief Operating Officer | Sale | 18,652 | $44K | Feb 9 | SEC ↗ | |
Keutzer TimothyFirst filing | Chief Operating Officer | Sale | 18,891 | $42K | Feb 5 | SEC ↗ |
Keutzer TimothyFirst filing | Chief Operating Officer | Sale | 24,224 | $52K | Feb 5 | SEC ↗ |
Keutzer TimothyFirst filing | Chief Operating Officer | Sale | 3,471 | $8K | Feb 5 | SEC ↗ |
Rajavelu EstherFirst filing | See Remarks | Sale | 18,442 | $41K | Feb 4 | SEC ↗ |
Related companies
Spero Therapeutics, Inc. is in the Healthcare sector.